---
title: "Citi Reaffirms Their Buy Rating on Sun Pharmaceutical Industries Limited (SUNPHARMA)"
description: "According to TipRanks, Agrawal CFA is an analyst with an average return of -4.6% and a 47.06% success rate. Agrawal CFA covers the Healthcare sector, focusing on stocks such as Sun Pharmaceutical Indu"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/259561251.md"
published_at: "2025-09-30T14:05:04.000Z"
---

# Citi Reaffirms Their Buy Rating on Sun Pharmaceutical Industries Limited (SUNPHARMA)

> According to TipRanks, Agrawal CFA is an analyst with an average return of -4.6% and a 47.06% success rate. Agrawal CFA covers the Healthcare sector, focusing on stocks such as Sun Pharmaceutical Industries Limited, Aurobindo Pharma Ltd, and Gland Pharma Ltd.. Currently, the analyst consensus on Sun Pharmaceutical Industries Limited is a Strong Buy with an average price target of INR1,934.25, representing a 21.32% upside. In a report released yesterday, Macquarie also maintained a Buy rating on the stock with a INR2,000.00 price target.

According to TipRanks, Agrawal CFA is an analyst with an average return of \-4.6% and a 47.06% success rate. Agrawal CFA covers the Healthcare sector, focusing on stocks such as Sun Pharmaceutical Industries Limited, Aurobindo Pharma Ltd, and Gland Pharma Ltd..

Currently, the analyst consensus on Sun Pharmaceutical Industries Limited is a Strong Buy with an average price target of INR1,934.25, representing a 21.32% upside. In a report released yesterday, Macquarie also maintained a Buy rating on the stock with a INR2,000.00 price target.

### Related Stocks

- [SUN.US - Sunoco LP](https://longbridge.com/en/quote/SUN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Vanda 制药｜8-K：2025 财年 Q4 营收 57.22 百万美元不及预期 |  | [Link](https://longbridge.com/en/news/275657004.md) |
| Vanda 制药｜10-K：2025 财年营收 2.16 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/275753219.md) |
| Jubilant Foodworks 第三季度合并净利润达到 7.09 亿卢比 | Jubilant Foodworks Ltd：第三季度合并净利润为 7.09 亿印度卢比；第三季度合并营业收入为 243.7 亿印度卢比；第三季度业绩包括一次性费用 3.37 亿印度卢比，其中包括新劳动法的影响 | [Link](https://longbridge.com/en/news/275443949.md) |
| 双威医疗保健委任六家投行担任上市承销商 \| 联合早报网 | 双威医疗保健（Sunway Healthcare）已委任六家投资银行作为首次公开售股（IPO）的承销商，计划在马来西亚上市，预计集资超过 30 亿令吉，估值将超过 150 亿令吉。承销商包括马来亚、艾芬黄氏、联昌国际、兴业、肯纳格及大马投资 | [Link](https://longbridge.com/en/news/275451558.md) |
| TVS Srichakra 宣布重新任命 R Naresh 为董事总经理，任期为三年 | TVS Srichakra Ltd：重新任命 R Naresh 为董事总经理，任期三年。12 月季度合并净利润为 1.115 亿印度卢比。12 月季度合并营业收入为 91.7 亿印度卢比 | [Link](https://longbridge.com/en/news/275714286.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.